2. Search Result
Search Result
Results for "

learning. memory

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0459
    3,5-O-Dicaffeoylquinic acid
    1 Publications Verification

    		 Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid
  • HY-N0541
    Pseudoginsenoside F11
    1 Publications Verification

    Ginsenoside A1

    		 Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-122150
    AMPA receptor modulator-3

    		iGluR Neurological Disease
    AMPA receptor modulator-3 is an allosteric AMPA receptor modulator (EC50: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory .
    AMPA receptor modulator-3
  • HY-P99216
    Ponezumab
    1 Publications Verification

    PF-04360365; RN 1219

    		 EGFR Neurological Disease
    Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
    Ponezumab
  • HY-17553
    Coluracetam
    3 Publications Verification

    MKC-231

    		 iGluR Neurological Disease
    Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .
    Coluracetam
  • HY-117984
    RU 35929

    		Drug Derivative Neurological Disease
    RU 35929 is a nootropic agent. RU 35929 enhances learning and memory .
    RU 35929
  • HY-19692
    Itasetron

    DA 6215; U98079A

    		 5-HT Receptor Neurological Disease
    Itasetron (DA 6215) is a selective 5-HT3 receptor antagonist. Itasetron improves spatial learning and memory abilities in the aged rat. Itasetron has potent antiemetic properties. Itasetron is used for age-related memory degeneration in rodents .
    Itasetron
  • HY-119061
    SB357134

    		5-HT Receptor Neurological Disease
    SB-357134 is a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. SB-357134 enhances memory and learning and increases seizure threshold in rats .
    SB357134
  • HY-N0459R
    3,5-O-Dicaffeoylquinic acid (Standard)

    		Reference Standards Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,5-O-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid (Standard)
  • HY-143464
    BChE-IN-4

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-4 is a potent and cross the blood-brain barrier BChE inhibitor. BChE-IN-4 attenuates learning and memory deficits caused by cholinergic deficit in mouse model. BChE-IN-4 has the potential for the research of alzheimer’s disease .
    BChE-IN-4
  • HY-124244
    DB-959

    PPARδ/γ agonist 1

    		 PPAR Neurological Disease
    DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD). .
    DB-959
  • HY-P3684A
    [DPro5] Corticotropin Releasing Factor, human, rat TFA

    		CRFR Neurological Disease
    [DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat TFA
  • HY-B0978
    Diethyltoluamide

    DEET; N,N-Diethyl-m-toluamide

    		 Parasite Infection Neurological Disease
    Diethyltoluamide (DEET) is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Diethyltoluamide is toxic to hepatocytes and can lead to many physiological, pharmacological, and behavioral abnormalities, particularly motor deficits and learning and memory dysfunction .
    Diethyltoluamide
  • HY-114239
    JBPOS-0101

    		Amyloid-β Neurological Disease
    JBPOS-0101 is a phenyl carbamate compound. JBPOS-0101 exhibits neuroprotective and antiepileptic effects. JBPOS-0101 can attenuate the accumulation of Aβ in 5XFAD mouse brains and rescue the deficits in learning and memory. JBPOS-0101 can be used for the research of neurological disease, such as Alzheimer's disease (AD) .
    JBPOS-0101
  • HY-155126
    LZWL02003

    		Reactive Oxygen Species (ROS) Neurological Disease
    LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP +-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .
    LZWL02003
  • HY-131892
    2-Deoxy-D-galactose
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease Cancer
    2-Deoxy-D-galactose is a glucose analog. 2-Deoxy-D-galactose inhibits glycolysis to inhibits tumor growth. 2-Deoxy-D-galactose is a substance interfering with the fucosylation of glycomacromolecules and impairing memory consolidation in various learning tasks. 2-Deoxy-d-galactose hinders glycoprotein fucosylation in vivo .
    2-Deoxy-D-galactose
  • HY-115864
    Osavampator

    TAK-653; NBI-1065845

    		 iGluR Lipoxygenase Neurological Disease
    Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca 2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
    Osavampator
  • HY-146086
    Nrf2 activator-4

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model .
    Nrf2 activator-4
  • HY-W011370
    Pelargonidin chloride
    1 Publications Verification

    		 Quinone Reductase Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Pelargonidin chloride is an anthocyanidin and also is a scavenger of nitric oxide radical and has antioxidant activities. Pelargonidin inhibits cell viability and induces cell cycle arrest at sub-G1 phase. Pelargonidin chloride increases the mRNA and protein expression of HO-1, NQO1, Nrf2. Pelargonidin chloride improves Aβ-induced memory and learning impairment .
    Pelargonidin chloride
  • HY-P3684
    [DPro5] Corticotropin Releasing Factor, human, rat

    		CRFR Endocrinology
    [DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat
  • HY-B0978R
    Diethyltoluamide (Standard)

    DEET (Standard); N,N-Diethyl-m-toluamide (Standard)

    		 Reference Standards Parasite Infection Neurological Disease
    Diethyltoluamide (Standard) is the analytical standard of Diethyltoluamide. This product is intended for research and analytical applications. Diethyltoluamide (DEET) is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Diethyltoluamide is toxic to hepatocytes and can lead to many physiological, pharmacological, and behavioral abnormal ities, particularly motor deficits and learning and memory dysfunction .
    Diethyltoluamide (Standard)
  • HY-108157
    A-72055

    		mAChR Neurological Disease
    A-72055 is a partial agonist of muscarinic receptors. A-72055 has binding activity to both M1 and M2 receptors, with Ki values of 32 nM and 30 nM, respectively. A-72055 can enhance cognitive function and improve learning and memory deficits. A-72055 has better security. A-72055 can be used for research on neurological disorders such as cognitive impairment .
    A-72055
  • HY-P10506
    CMX-8933

    		JNK Neurological Disease
    CMX-8933 is an octapeptide fragment of the goldfish brain neurotrophic factor ependymin. CMX-8933 increases the enzymatic activity of c-Jun N-terminal kinase (JNK), increases the phosphorylation of JNK and c-Jun proteins, and increases the cellular levels of c-Jun and c-Fos mRNA. CMX-8933 can be used to study the role of ependymin in neuroplasticity, learning, memory formation, and neural regeneration .
    CMX-8933
  • HY-100784
    Dihydrokainic acid
    1 Publications Verification

    		 EAAT Neurological Disease
    Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory .
    Dihydrokainic acid
  • HY-100406
    (S)-MCPG
    1 Publications Verification

    (+)-MCPG

    		 mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .
    (S)-MCPG
  • HY-148325
    α7 Nicotinic receptor agonist-1

    		nAChR Neurological Disease
    α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
    α7 Nicotinic receptor agonist-1
  • HY-135483A
    AR-R17779 hydrochloride

    		nAChR Neurological Disease
    AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with Kis of 92 and 16000 nM for α7 and α4β2 subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .
    AR-R17779 hydrochloride
  • HY-142701
    SSTR4 agonist 4

    		Somatostatin Receptor Neurological Disease
    SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .
    SSTR4 agonist 4
  • HY-123037
    Triadimefon

    		Fungal Akt PERK AMPK Infection Neurological Disease Metabolic Disease Endocrinology
    Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory .
    Triadimefon
  • HY-142700
    SSTR4 agonist 3

    		Somatostatin Receptor Neurological Disease
    SSTR4 agonist 3 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .
    SSTR4 agonist 3
  • HY-124086
    BHQ-O-5HT

    		5-HT Receptor Neurological Disease
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions .
    BHQ-O-5HT
  • HY-107719
    D-AP7

    		iGluR Neurological Disease
    D-AP7 is a specific NMDA receptor antagonist with inhibitory activity against epileptiform activity. D-AP7 attenuated neuronal activation in spot activity by reducing the duration and number of exogenously induced bursts. D-AP7 also increased the amplitude of secondary action potentials, which may restore neuronal activity in some epileptiform bursts. D-AP7 showed anxiogenic effects and impaired memory consolidation in passive avoidance learning .
    D-AP7
  • HY-149287
    hAChE/hBACE-1-IN-1

    		Cholinesterase (ChE) Neurological Disease
    hAChE/hBACE-1-IN-1 (compounds 5d) is an orally active inhibitor of hAChE with blood-brain permeability. hAChE/hBACE-1-IN-1 inhibits hAChE and hBACE-1 with IC50 values of 0.076 and 0.23 μM, respectively. hAChE/hBACE-1-IN-1 inhibits Aβ1-42 aggregation and improves mouse learning and memory ability. hAChE/hBACE-1-IN-1 can be used to research in Alzheimer's disease .
    hAChE/hBACE-1-IN-1
  • HY-17638A
    Mizagliflozin (sebacate)

    DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)

    		 SGLT Neurological Disease
    Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models .
    Mizagliflozin (sebacate)
  • HY-162681
    eeAChE-IN-3

    		Cholinesterase (ChE) Interleukin Related Neurological Disease
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research .
    eeAChE-IN-3
  • HY-168966
    JNJ-54082730

    		Phosphodiesterase (PDE) iGluR Neurological Disease
    JNJ-54082730 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits PDE2A, PDE3B, and PDE10A2 with IC50s of 0.95 nM, 6.17 μM (pIC50=5.21) and 87.1 nM (pIC50=7.06), respectively. JNJ-54082730 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. JNJ-54082730 can cross blood-brain barrier .
    JNJ-54082730
  • HY-123037R
    Triadimefon (Standard)

    		Reference Standards Fungal Akt PERK AMPK Infection Neurological Disease Metabolic Disease Endocrinology
    Triadimefon (Standard) is the analytical standard of Triadimefon (HY-123037). This product is intended for research and analytical applications. Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory .
    Triadimefon (Standard)
  • HY-W987949
    Z-4105

    		Others Neurological Disease
    Z-4105 (formula l) is a nootropic agent. Z-4105 restores the amnesic effect of electroconvulsive ehock (ECS) and methylazoxymethanol acetate (MAM), improving learning and memory function. Z-4105 increases the activity of the brain cholinergic system without affecting other neurotransmitter systems. Z-4105 significantly attenuates the neuropathic pain induced by chronic constrictive lesion (CCl) in the sciatic nerve of rat hind leg models and in the ligament of rat spinal nerve models. Z-4105 can be used for neuropathic pain and cerebral dysfunctional disorders research .
    Z-4105
  • HY-NP0204
    Mouse Serum Albumin

    		ELOVL Apoptosis NOD-like Receptor (NLR) Caspase Tau Protein Neurological Disease Inflammation/Immunology
    Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .
    Mouse Serum Albumin
  • HY-B2167R
    Docosahexaenoic acid (Standard)

    DHA (Standard); Cervonic acid (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
    Docosahexaenoic acid (Standard)
  • HY-175841
    Tau Protein Phosphorylation-IN-1

    		Tau Protein p38 MAPK NF-κB Apoptosis Bcl-2 Family ERK JNK Neurological Disease
    Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that potently protects PC12 cells against Aβ25–35-induced cytotoxicity (EC50 = 1.93 μM), and can penetrate the blood-brain barrier (BBB).Tau Protein Phosphorylation-IN-1 reverses the hyperphosphorylation of tau, significantly inhibits the expression of certain immune-related cytotoxic factors, suppresses the MAPK and NF-κB signaling pathways, and significantly inhibits the expression of RAGE and the apoptosis factors Bax/Bcl-2, both in vitro and in vivo. Tau Protein Phosphorylation-IN-1 relieves nerve damage, and improves learning and memory in an Alzheimer’s disease (AD) mouse model. Tau Protein Phosphorylation-IN-1 can be used for AD research .
    Tau Protein Phosphorylation-IN-1
  • HY-162812
    H3R antagonist 4

    		Apoptosis Cholinesterase (ChE) Tau Protein Ferroptosis Histamine Receptor Neurological Disease
    H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC50 of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ1-42 induced by itself and Cu 2+ (95.48% and 88.63%) , and degraded the Aβ1-42 fibrils induced by itself and Cu 2+ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu 2+, Zn 2+, Al 3+, and Fe 2+. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .
    H3R antagonist 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: